Additionally, the company is seeking further indications for antiplatelet agent Prasugrel, marketed as Effient in the U.S. in cooperation with Eli Lilly and Co. The company is hoping to recoup its leadership in the U.S. injectable iron market through the launch of Injectafer for iron deficiency anemia. Luitpold Pharmaceuticals, a Daiichi Sankyo Group Co. headquartered in Shirley, NY, is positioning this next-generation product to succeed the struggling anemia treatment Venofer in the niche injectables market. Luitpold is also plans to release competitive generic injectables onto the market. LPI experienced a 5.4 billion yen decline in sales as mainstay product Venofer was negatively affected by competing products, and LPI itself was affected by a warning issued by the FDA in the early part of the FY11 concerning its plant in Shirley.